Interventional Imaging Solutions

Interventional Imaging Solutions

Beyond diagnostic medical imaging, Guerbet is accelerating its expansion in the interventional radiology field. We aim to provide the interventional medical community with innovative image-guided solutions to help physicians advance their patients’ treatments.

Guerbet Offerings within Interventional Imaging

Guerbet is a global leader in contrast media and solutions for diagnostic and interventional radiology, which includes the imaging of tumors in adults with known HCC, as well as microcatheter embolization of vascular anomalies.

In early 2018, Guerbet acquired Accurate Medical Therapeutics (“Accurate”). Accurate developed a range of microcatheters for embolization procedures on tumors or vascular diseases. Guerbet continues to invest in cutting edge technology, which aims to supplement our existing interventional imaging portfolio and other significant synergies with our range of products.

Overall, the focus of our Interventional Imaging franchise is to provide interventional radiologists with innovative image-guided and minimally invasive solutions that help advance the treatment of patients.

Lipiodol Logo (TEST)

Lipiodol® (Ethiodized Oil) Injection

Iodinated ethyl esters of fatty acids of poppyseed oil. Discovered by Marcel Guerbet in 1901, Lipiodol® (Ethiodized Oil) was the first iodinated contrast agent launched in the world. It was first used in radiology in France in 1921. Currently, Lipiodol® (Ethiodized Oil) is mainly used in Interventional Radiology and Women’s Health. Visit Lipiodol® (Ethiodized Oil) Injection for more information. 

Interventional Radiology
Women's Health

Drakon Logo (TEST)

Drakon™ Peripheral Microcatheters

The Drakon™ microcatheters are intended for the infusion of contrast media into all peripheral vessels. The Drakon™ microcatheters are also intended for drug infusion in intra-arterial therapy and infusion of embolic materials. The Drakon™ microcatheters should not be used in cerebral vessels. Visit Drakon™ Peripheral Microcatheters for more information.

Interventional Radiology
Women's Health 
Men's Health

Sequre (TEST)

SeQure® Reflux Control Microcatheters

The SeQure® microcatheters are intended for the infusion of contrast media into all peripheral vessels. The SeQure® microcatheters are also intended for drug infusion in intra-arterial therapy and infusion of embolic materials. The SeQure® microcatheters should not be used in cerebral vessels. Visit SeQure® Reflux Control Microcatheters for more information. 

Interventional Radiology
Women's Health
Men's Health

Important Safety Information 

WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY

See Full Prescribing Information for complete Boxed Warning.

Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose.

Important Safety Information (Continued)

Indication and Usage

LIPIODOL® (ethiodized oil) injection is a prescription oil-based radio-opaque contrast agent indicated for:

  • hysterosalpingography in adults
  • lymphography in adult and pediatric patients
  • selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

Contraindications

LIPIODOL® is contraindicated in patients with hypersensitivity to LIPIODOL®, hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding.

  • LIPIODOL® Hysterosalpingography is contraindicated in pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre-or postmenstrual phase, or within 30 days of curettage or conization.
  • LIPIODOL® Lymphography is contraindicated in patients with a right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage, advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to the examined area.
  • LIPIODOL® Selective Hepatic Intra-arterial Injection is contraindicated in the presence of dilated bile ducts unless external biliary drainage was performed before injection.

 Warnings and Precautions

  • Pulmonary and cerebral embolism may occur immediately or after a few hours to days from inadvertent systemic vascular injection or intravasation of LIPIODOL®. Avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload.
  • Anaphylactoid and anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following LIPIODOL® Avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL®.
  • LIPIODOL® hepatic intra-arterial administration can exacerbate chronic liver disease.
  • Iodinated contrast media can affect thyroid function because of the iodide content and can cause hyperthyroidism or hypothyroidism.

Adverse Reactions

  • Hysterosalpingography – Abdominal pain, foreign body reactions, exacerbation of pelvic inflammatory disease, salpingitis or pelvic peritonitis have been reported after the examination in case of latent infection.
  • Lymphography – Lymphangitis, thrombophlebitis, edema or exacerbation of preexisting lymphedema, dyspnea and cough, iodism, allergic dermatitis, lipogranuloma, delayed healing at the site of incision.
  • Selective Hepatic Intra-arterial Injection – Abdominal pain, nausea, and vomiting are the most common reactions; other reactions include hepatic vein thrombosis, hepatic ischemia, liver enzymes abnormalities, transitory decrease in liver function, liver decompensation and renal insufficiency. Procedural risks include vascular complications and infections.

Use in Specific Populations

  • Pregnancy: The use of LIPIODOL® before or during pregnancy may interfere with thyroid function in both the pregnant woman and her fetus and may affect fetal development. Untreated hypothyroidism in pregnancy is associated with adverse perinatal outcomes, such as spontaneous abortion, preeclampsia, preterm birth, abruptio placentae, and fetal death. The use of LIPIODOL® before or during pregnancy causes iodide transfer across the placenta which may interfere with fetal thyroid function and may affect fetal development. Untreated hypothyroidism is also associated with increased fetal risk of low birth weight, fetal distress, and impaired neuropsychological development. Consider thyroid function testing during pregnancy if a woman was exposed to LIPIODOL® either before or during pregnancy, and also in infants whose mothers were exposed to LIPIODOL® before and during pregnancy or if clinically indicated.
  • Pregnancy Testing: Confirm that the patient has a negative pregnancy test within 24 hours before LIPIODOL® administration for hysterosalpingography.
  • Lactation: The use of LIPIODOL® may increase the concentration of iodide in human milk and may interfere with the thyroid function of the breastfed infant. Consider thyroid function testing in a breastfed infant whose mother was exposed to LIPIODOL® or if clinically indicated.
  • Pediatric: For lymphography use a dose of minimum of 1 mL to a maximum of 6 mL according to the anatomical area to be visualized. Do not exceed 0.25 mL/kg. Administer the smallest possible amount of LIPIODOL® according to the anatomical area to be visualized.
  • Geriatric: There are no studies conducted in geriatric patients.
  • Renal Impairment: Prior to an intra-arterial administration of LIPIODOL® screen all patients for renal dysfunction by obtaining history and/or laboratory tests. Consider follow-up renal function assessments for patients with a history of renal dysfunction.

For more information, see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

SeQure and Drakon are Class II medical devices intended for use by interventional radiologists and interventional oncologists for the infusion of contrast media into all peripheral vessels, for drug infusion in intra-arterial therapy, and for infusion of embolic materials. They should not be used in cerebral vessels.

For complete information about precautions and optimal usage conditions for these medical devices, we recommend consulting the instructions for use supplied with each device or with your local Guerbet representative(s).

Caution: US Federal Law restricts this device to sale by or on the order of a physician.

GU05201138